Versailles Hospital
86
12
14
40
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
3.5%
3 terminated/withdrawn out of 86 trials
93.0%
+6.5% vs industry average
6%
5 trials in Phase 3/4
0%
0 of 40 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (86)
Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma
Role: lead
Techniques for Activating Consciousness (TAC) for Outpatients With Moderate to Severe Alcohol Addiction
Role: lead
Efficacy of an Empirical Treatment With Amoxicillin-clavulanate (AC) Compared to the Combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the Outpatient Care of Chemotherapy-induced Fever in Adult Haematology Patients.
Role: lead
Descriptive Study of the Reconstruction of Osteochondral Lesions of the Knee: Clinical and Imaging Results
Role: lead
Cross-cultural Adaptation and Validation of the French Version of the Social Media Disorder Scale for Parents in a Sample of Parents of Children Aged 10 to 17
Role: lead
Descriptive Study of Multiligamentary Reconstruction of the Knee
Role: lead
Targeted Hypothermia Versus Targeted Normothermia After Convulsive Refractory Status Epilepticus
Role: lead
Retrospective, Observationnal Study to Investigate Procedural Analgesia Delivered to Patients With Lacerations, Abrasions, Burns and Leg Ulcers.
Role: lead
Prophylactic Anti-aRrhythmic Therapy With Amiodarone in Critically Ill Patients Admitted for an Out-of-hospital Cardiac Arrest With Initial Shockable Rhythm
Role: lead
Adapting the FACETS Program to Sickle Cell Disease
Role: lead
National Multicentre Study of the Natural History of Acid Sphingo-myelinase Deficiency in Adults and Children
Role: collaborator
Creation of a Syncope Channel for Patients Admitted to the Emergency Department for Loss of Consciousness and Not Hospitalized: Etiological Predictivity (Before/After Study)
Role: lead
Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients
Role: lead
Explorations of the Normal Neural Behavioral and Pathological Bases of Metacognition
Role: lead
Patient-reported Outcome After Status Epilepticus
Role: lead
Patient-reported Outcome and Patient-reported Experience After Status Epilepticus
Role: lead
Development and Validation of a Language Screening Test in Acute Right Hemispheric Strokes
Role: lead
Chronic Myeloid Leukemia (CML) Real-Life Database
Role: collaborator
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors
Role: collaborator
Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4
Role: lead